<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Ophthalmol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Ophthalmol Rep</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Current Ophthalmology Reports</journal-title></journal-title-group><issn pub-type="epub">2167-4868</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474738</article-id><article-id pub-id-type="pmcid-ver">PMC12474738.1</article-id><article-id pub-id-type="pmcaid">12474738</article-id><article-id pub-id-type="pmcaiid">12474738</article-id><article-id pub-id-type="doi">10.1007/s40135-025-00337-6</article-id><article-id pub-id-type="publisher-id">337</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>3D Bioprinting of Cellular Therapeutic Systems in Ophthalmology: from Bioengineered Tissue to Personalized Drug Delivery</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hyeonji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ngo</surname><given-names initials="GH">Gia-Han</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hong</surname><given-names initials="W">Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="SH">Soo Hyeon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahajan</surname><given-names initials="VB">Vinit B.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>DeBoer</surname><given-names initials="C">Charles</given-names></name><address><email>cdeboer@stanford.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03mtd9a03</institution-id><institution-id institution-id-type="GRID">grid.240952.8</institution-id><institution-id institution-id-type="ISNI">0000000087342732</institution-id><institution>Department of Ophthalmology, School of Medicine, </institution><institution>Byers Eye Institute at Stanford University, </institution></institution-wrap>Palo Alto, CA 94304 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Molecular Surgery Laboratory, </institution><institution>Stanford University, </institution></institution-wrap>Palo Alto, CA 94304 USA </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>13</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><elocation-id>10</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 14:25:15.427"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40135_2025_Article_337.pdf"/><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">In this article, we provide a brief overview of 3D bioprinting technologies and the types of cells employed in ophthalmic cell therapy. We then explore recent applications of 3D bioprinting in ophthalmic cell delivery systems.</p></sec><sec><title>Recent Findings</title><p id="Par2">Cell therapy in ophthalmology is a promising treatment for various eye diseases, there exists some limitations of existing cell therapy strategies Such as cell loss, poor integration with Surrounding tissues, and the sustainability of long-term effects. In this regard, 3D bioprinting technology provides a beneficial method for developing highly biomimetic and reliable cell delivery systems for ophthalmic disease research. Recent advances have shown bioengineered tissues which replicate the microstructure of native tissues, personalized ophthalmic devices, and encapsulated cell-delivery systems. While still in the early stages of advancement, the development of cell delivery systems based on bioprinting technologies is indeed inspiring and has the potential to be applied to other ocular diseases.</p></sec><sec><title>Summary</title><p id="Par3">Cell therapy based on 3D bioprinting technology in ophthalmology has great potential in ophthalmic disease treatment as well as ocular tissue engineering and regenerative medicine.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Drug delivery</kwd><kwd>Cell therapy</kwd><kwd>3D bioprinting technology</kwd><kwd>Tissue engineering</kwd><kwd>Regenerative medicine</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100001818</institution-id><institution>Research to Prevent Blindness</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30-EY026877</award-id><award-id>P30-EY026877</award-id><award-id>P30-EY026877</award-id><award-id>P30-EY026877</award-id><award-id>P30-EY026877</award-id><award-id>P30-EY026877</award-id><principal-award-recipient><name name-style="western"><surname>Kim</surname><given-names>Hyeonji</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>Gia-Han</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Wen</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Soo Hyeon</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>Vinit B.</given-names></name><name name-style="western"><surname>DeBoer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Stanford Center for Optic Disc Drusen</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007817</institution-id><institution>Alcon Research Institute</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>The Robert Machemer Foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010310</institution-id><institution>E. Matilda Ziegler Foundation for the Blind</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006312</institution-id><institution>BrightFocus Foundation</institution></institution-wrap></funding-source><award-id>M2025004N</award-id><principal-award-recipient><name name-style="western"><surname>DeBoer</surname><given-names>Charles</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Cell therapy in ophthalmology is a promising treatment for various eye diseases, from corneal damage to retinal degeneration [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. It has progressed towards personalized medicine that enables targeted cell-based delivery tailored to individual patient needs and has provided long-term drug delivery of proteins in degenerative eye disease. However, several challenges remain in the clinical and practical application of cell therapies, particularly concerning cell viability and function, caused by cell loss, poor integration with surrounding tissues, and the sustainability of long-term effects [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Recently, hydrogels, encapsulation, and scaffolds, aimed at creating supportive environments for transplanted cells, have improved retention and therapeutic efficacy [<xref ref-type="bibr" rid="CR5">5</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. With tremendous advances, some cell delivery systems are clinically available for specific ocular diseases, and some cell-based therapeutic systems are under evaluation in large clinical trials for conditions like glaucoma [<xref ref-type="bibr" rid="CR8">8</xref>]. Yet, significant hurdles, such as poor bioavailability and immune activation, continue to hold back progress. Therefore, there still exists the need for novel cell delivery systems that can effectively resolve such challenges and optimize the therapeutic effects of cell-based treatments.</p><p id="Par5">3D bioprinting is a powerful technology in the medical field, wherein biomaterials&#8212;including cells&#8212;are deposited in a controlled, layer-by-layer manner. This capability enables fabrication of complex biological constructs customized to individual patient needs, addressing existing limitations in traditional cell delivery systems by improving cell retention and integration with host tissues [<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, various 3D bioprinting approaches have been developed to reduce immune rejection and inflammatory responses by providing a more natural and structured environment for both transplanted cells and those recruited from Surrounding tissues. This review will focus on cell-based therapies based on 3D bioprinting technology (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). We will begin with a brief overview of 3D bioprinting technologies and the types of cells employed in ophthalmic cell therapy. Subsequently, we will explore recent applications of 3D bioprinting in ophthalmic cell delivery systems, particularly in the development of bioengineered tissues and therapeutic systems using encapsulated cell therapy (ECT).</p><p id="Par6">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Overview of 3D bioprinting in ophthalmic applications</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40135_2025_337_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec2"><title>3D Bioprinting Technologies</title><p id="Par7">3D bioprinting has emerged as a transformative technology in regenerative medicine, enabling the construction of complex biological systems, including functional tissues such as vasculature, muscle, and bone, as well as personalized therapeutic systems capable of drug delivery [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, the versatility of bioprinting technology can also allow direct printing of actual living cells, which has introduced a new fabrication technique to the field of cell therapy and drug delivery. In ophthalmology, this technology is particularly promising due to its ability to create micro-precision, layered tissues, and patient-specific tissue grafts with minimum immune rejection [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. These characteristics may facilitate advancements in implantable tissues, tissue models for drug testing, and cell-laden therapeutic systems.</p><p id="Par8">There are three main types of 3D bioprinting technologies, each with its own set of strengths and weaknesses: <italic toggle="yes">extrusion</italic>,<italic toggle="yes"> laser-assisted</italic>, and <italic toggle="yes">inkjet bioprinting</italic> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR9">9</xref>]. Despite distinct differences, these technologies have all shown potential for personalized therapy on a small scale. The printing method would be selected depending on the desired structure. Once selected, various parameters including material viscosity, nozzle size, printing time, and printing pressure, can be adjusted to control not only external topography but also internal features such as shape, size, porosity, and interconnectivity [<xref ref-type="bibr" rid="CR13">13</xref>]. These factors are critical to provide Sufficient oxygen and nutrients, necessary for tissue integration and functionality. Various manufacturing approaches have also been developed to address specific 3D bioprinting limitations. For example, bath printing offers structural support during printing, which allows fabrication of complex geometries. Further, the aqueous environment supports cell longevity while printing [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. The fabricated structures support the transplanted or recruited cells&#8217; attachment, growth, and maintenance of physiological functions.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Overview of various 3D Bioprinting technologies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1">Technology Type</th><th align="left" colspan="1" rowspan="1">Description</th><th align="left" colspan="1" rowspan="1">Resolution</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Extrusion Bioprinting</td><td align="left" colspan="1" rowspan="1">Employs a syringe-based system to extrude bioinks, enabling the creation of macroscale structures or structures with high cell density.</td><td align="left" colspan="1" rowspan="1">Tens of &#8722;500&#160;&#956;m</td><td align="left" colspan="1" rowspan="1"><p>- High cell density</p><p>- Suitable for a variety of materials</p></td><td align="left" colspan="1" rowspan="1"><p>- Lower resolution</p><p>- Requires precise control</p></td></tr><tr><td align="left" rowspan="2" colspan="1">Laser-Assisted Bioprinting</td><td align="left" colspan="1" rowspan="1">Stereolithography (SLA) and Digital Light Processing (DLP)</td><td align="left" colspan="1" rowspan="1">Employ light source to cure photosensitive bioinks layer by layer using UV or digital light.</td><td align="left" colspan="1" rowspan="1">0.5&#8211;100&#160;&#956;m</td><td align="left" colspan="1" rowspan="1"><p>- High resolution</p><p>- Smooth surface finish</p><p>- Fast printing speed (DLP)</p></td><td align="left" colspan="1" rowspan="1"><p>- Limited material options</p><p>- Requires post-processing</p></td></tr><tr><td align="left" colspan="1" rowspan="1">laser-induced forward transfer (LIFT)</td><td align="left" colspan="1" rowspan="1">Utilizes laser energy to transfer bioinks onto a substrate, minimizing cell damage during the printing process.</td><td align="left" colspan="1" rowspan="1">50&#8211;100&#160;&#956;m</td><td align="left" colspan="1" rowspan="1"><p>- High precision</p><p>- Minimal cell damage</p></td><td align="left" colspan="1" rowspan="1"><p>- Complex setup</p><p>- Higher cost</p></td></tr><tr><td align="left" colspan="2" rowspan="1">Inkjet Bioprinting</td><td align="left" colspan="1" rowspan="1">Utilizes inkjet technology to deposit bioinks layer by layer, allowing for precise placement of cells and biomaterials.</td><td align="left" colspan="1" rowspan="1">20&#8211;100&#160;&#956;m (1&#8211;10 nL of droplet)</td><td align="left" colspan="1" rowspan="1"><p>- High resolution</p><p>- Low viscous materials</p></td><td align="left" colspan="1" rowspan="1"><p>- Limited cell density</p><p>- Slower printing speed</p></td></tr></tbody></table></table-wrap></p><p id="Par9">3D bioprinting applications of ophthalmic cell therapy include direct printing of hydrogel-type bioinks containing cells to replicate tissues like the cornea and retina (covered in "<xref rid="Sec4" ref-type="sec">3D Bioprinted Ophthalmic Tissues</xref>" section), and the development of therapeutic cell delivery systems by printing biomaterials to create frameworks for cell injection (covered in "<xref rid="Sec10" ref-type="sec">Encapsulated Cell Therapy and Applications for 3D Printing</xref>" section). These advancements enhance the study of disease progression, biological mechanisms of tissue, and drug action, contributing to personalized regenerative medicine.</p></sec><sec id="Sec3"><title>Cells Used in Ophthalmic Cell Therapy and their Potential for Use with 3D Bioprinting</title><p id="Par10">Effective 3D bioprinting for ophthalmic cell delivery relies significantly on cell sources that have strong therapeutic potential (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Stem cells are valuable due to their ability for self-renewal and differentiation into specific ocular cell types, including epithelial, photoreceptor, and endothelial cells [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. Among these, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are pluripotent, offering potential for regenerative therapies, although ESCs face ethical issues [<xref ref-type="bibr" rid="CR22">22</xref>]. Conversely, mesenchymal stem cells (MSCs) have the potential to differentiate into adult cell types, with their properties varying based on their tissue origin (e.g., dental pulp, bone marrow, and adipose tissue) [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Their strong immunosuppressive properties and lower risk of tumorigenicity compared to ESCs and iPSCs also make them advantageous for therapeutic use. Non-stem cells in regenerative medicines offer advantages by leveraging their intrinsic cellular function, avoiding ethical concerns, minimizing the risk of tumorigenesis, and reducing immunogenicity using autologous (patient-derived) cells. Oral mucosal epithelial cells (OMECs) [<xref ref-type="bibr" rid="CR28">28</xref>]peripheral blood mononuclear cells (PBMCs) [<xref ref-type="bibr" rid="CR28">28</xref>]limbal epithelial cells [<xref ref-type="bibr" rid="CR29">29</xref>]corneal endothelial cells [<xref ref-type="bibr" rid="CR30">30</xref>]photoreceptor precursor cells [<xref ref-type="bibr" rid="CR18">18</xref>]and retinal pigment epithelium (RPE) [<xref ref-type="bibr" rid="CR31">31</xref>] are the ideal cell types for use in autologous graft-based therapies. Allogeneic (donor) retinal pigment epithelium (ARPE19) is also well-suited for expressing therapeutic proteins, such as neuroprotective therapies or VEGF receptors, due to their low tumorigenicity and immunogenicity [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, genetically modified cells can be engineered to improve therapeutic outcomes by delivering local therapeutic molecules binding to correct genetic defects, improving functional integration, and reducing the risk of immune rejection post-transplantation [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>]. Fouladi et al. employed a genetically engineered cornea graft (OXB-202) to express and deliver therapeutic proteins endostatin and angiostatin to suppress corneal neovascularization following transplantation [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par11">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Cell sources for regenerative therapies in ophthalmology </p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3" rowspan="1">Cell Sources</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Stem cell</td><td align="left" colspan="2" rowspan="1">ESCs</td><td align="left" colspan="1" rowspan="1">- Pluripotent, potentially unlimited source of cells.</td><td align="left" colspan="1" rowspan="1"><p>- Highest potential for tumor formation from undifferentiated human ESCs.</p><p>- Can trigger immune rejection from transplantation.</p><p>- Ethical concerns associated with culture from embryos.</p></td></tr><tr><td align="left" colspan="2" rowspan="1">iPSCs</td><td align="left" colspan="1" rowspan="1"><p>- Pluripotent by reactivation (easy accessibility and expandability).</p><p>- Avoids ethical concerns of culture from embryos.</p></td><td align="left" colspan="1" rowspan="1">- Possible tumorigenesis or teratoma formation.</td></tr><tr><td align="left" colspan="2" rowspan="1">MSCs</td><td align="left" colspan="1" rowspan="1">- Multipotent.</td><td align="left" colspan="1" rowspan="1">- Regulate tumor growth, invasion, metastasis.</td></tr><tr><td align="left" colspan="1" rowspan="1">Ocular stem cells</td><td align="left" colspan="1" rowspan="1">LECs, LSCs, TMSCs, CjSCs</td><td align="left" colspan="1" rowspan="1"><p>- Specialized for their target tissue.</p><p>- Amenable to autologous transplantation.</p><p>- Lower risk of tumorigenesis compared to ESCs/iPSCs.</p></td><td align="left" colspan="1" rowspan="1">- Obtaining a sufficient number of functional cells can be challenging.</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-stem cell</td><td align="left" colspan="2" rowspan="1">OMECs, PBMCs, LECs, CECs, Photoreceptor precursor cells, RPE</td><td align="left" colspan="1" rowspan="1"><p>- Leverage their instinct cellular function.</p><p>- Easier accessibility, and potentially reduced ethical concerns.</p><p>- Less likely to develop into tumors compared to stem cells.</p><p>- Autologous cell minimizes the risk of immune rejection.</p></td><td align="left" colspan="1" rowspan="1"><p>- Harvesting autologous cells causes donor site injury.</p><p>- It may be difficult to harvest sufficient quantities for reconstruction.</p></td></tr><tr><td align="left" colspan="3" rowspan="1">Gene-modified cells</td><td align="left" colspan="1" rowspan="1"><p>- Can be tailored to enhance therapeutic efficacy.</p><p>- Can correct genetic deficits.</p><p>- Can reduce the risk of immune rejection post-transplantation.</p></td><td align="left" colspan="1" rowspan="1"><p>- Potentially off-targets effects for gene editing.</p><p>- Safety concerns associated with gene delivery factors.</p><p>- Complexity and cost of production and selection.</p></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ESCs</italic> embryonic stem cells,&#160;<italic toggle="yes">iPSCs</italic> induced pluripotent stem cells, <italic toggle="yes">MSCs</italic> mesenchymal stem cells, <italic toggle="yes">LECs</italic> lens epithelial stem/progenitor cells, <italic toggle="yes">LSCs</italic> cornea limbal stem cells, <italic toggle="yes">TMSCs</italic> trabecular meshwork stem cells, <italic toggle="yes">CjSCs</italic> conjunctival epithelial stem cells, <italic toggle="yes">OMECs</italic> oral mucosal epithelial cells, <italic toggle="yes">PBMCs</italic> peripheral blood mononuclear cells, <italic toggle="yes">LECs</italic> limbal epithelial cells, <italic toggle="yes">CECs</italic> corneal endothelial cells, <italic toggle="yes">RPE</italic> retinal pigment epithelium</p></table-wrap-foot></table-wrap>
</p><p id="Par12">To Successfully integrate the aforementioned therapeutic cells into 3D bioprinting technology, several critical attributes must be considered: the ability to support the growth and survival of living cells (<italic toggle="yes">cell viability</italic>), the capacity to perform specialized functions required by the tissue (<italic toggle="yes">functionality</italic>), and the assurance of safe interaction with the body (<italic toggle="yes">biocompatibility</italic>). <italic toggle="yes">Cell viability</italic> is a critical factor in 3D bioprinting. Maintaining high <italic toggle="yes">cell viability</italic> is challenging, particularly for stem cells or primary cells, which are vulnerable to environmental stressors and can further influence cell signaling and protein expression [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. An improved strategy to reduce cell stress, for instance, in extrusion-based bioprinting is lowering extrusion pressure and using wider nozzles [<xref ref-type="bibr" rid="CR40">40</xref>]. SLA and DLP use photocrosslinking materials with LED light sources instead of cytotoxic UV-activated crosslinkers. Additionally, employing nature-derived polymers (e.g., alginate, collagen, gelatin) or injectable decellularized extracellular matrix (dECM) can create a cell-friendly environment conducive to cell survival [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. To mimic target tissue-specific extracellular matrix (ECM), hydrogel-based scaffolds have been developed [<xref ref-type="bibr" rid="CR43">43</xref>]. Agrawal et al. developed Kuragel, a photo-crosslinkable hydrogel and an ideal sacrificial matrix (a temporary structure used in 3D printing), which exhibits stromal cell survival by providing familiar ECM characteristics and promoting corneal regeneration [<xref ref-type="bibr" rid="CR44">44</xref>]. Engineering hydrogels have also been utilized in growing microvessel networks in vivo as a valuable tool to mimic ECMs [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Crosslinked collagen hydrogel has been found to generate endothelial cell-mediated vascular networks, an important design for cell-based delivery strategies [<xref ref-type="bibr" rid="CR47">47</xref>]. <italic toggle="yes">Functionality</italic> of 3D-printed tissues is another critical challenge that requires further attention. Achieving functional 3D-printed tissues depends on the biological behavior of cells embedded within the construct. Tan et al. demonstrated that mechanical cues like cyclic stretching can guide cell growth and lineage-specific differentiation, as seen with corneal fibroblasts maintaining shape under stretch [<xref ref-type="bibr" rid="CR48">48</xref>]. Incorporating bioactive molecules, such as growth factors like glia cell-derived neurotrophic factor (GDNF) into bioinks can further enhance tissue regeneration [<xref ref-type="bibr" rid="CR49">49</xref>]. Controlling cellular organization, such as cellular spatial distribution and alignment, is also a key factor that affects cell behavior. Samandari et al. address this challenge via a microcompartmentalization system containing GelMA to help with cell growth and alginate to provide cell alignment during cell maturation [<xref ref-type="bibr" rid="CR50">50</xref>]. These factors can essentially promote cellular activities, support tissue regeneration, and facilitate the establishment of a more physiologically relevant environment. <italic toggle="yes">Biocompatibility</italic> is an important factor in determining the viability of 3D printed biomaterials. Therefore, 3D bioprinted constructs need to be non-toxic, non-immunogenic, non-carcinogenic and preclude any adverse local or systemic effects. As previously noted, selecting non-toxic materials and implementing purification processes to eliminate toxic residues or solvents after printing are essential to avoid systemic toxicity. If the material is biodegradable, byproducts also need to behave likewise to prevent severe reactions [<xref ref-type="bibr" rid="CR51">51</xref>]. In addition to toxicity, such reactions may also lead to inflammatory responses caused by foreign materials, structures, and cells. To mitigate this, the infusion of immunomodulating cells and immunosuppressive molecules has been investigated. MSCs can improve immune regulation during tissue regeneration through cell-to-cell interaction with various immune cell types, such as monocytes and neutrophils [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. MSCs and hESC-derived RPE cells can inhibit the proliferation of activated T cells in vitro, reduce the secretion of pro-inflammatory cytokines such as interferon-&#947;, and enhance T cell apoptosis [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. The incorporation of immunosuppressive molecules such as cyclosporine A or tacrolimus can further prevent acute cellular rejection by blocking T cell activation and inhibiting IL-2 transcription, especially in high-risk corneal grafts [<xref ref-type="bibr" rid="CR55">55</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>]. In addition to the combination treatment, such as hematopoietic stem cells and Tr1-cell therapy tested in phase I-II trials may can overcome individual limitations and leverage unique immune-tolerating properties [<xref ref-type="bibr" rid="CR59">59</xref>]. Regulating the Surface properties of biomaterials after 3D printing can help reduce the risk of tumorigenesis by promoting the full differentiation of stem cells [<xref ref-type="bibr" rid="CR60">60</xref>]. For example, surface modification, particularly with self-assembled monolayers (SAMs) bearing functional groups, has been found to enhance cell-biomaterial interactions and induce stem cell differentiation. For example, the amino group (&#8211;NH<sub>3</sub>) promotes osteogenesis differentiation, and the methyl group (&#8211;CH<sub>3</sub>) supports chondrogenesis in human MSCs [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Those strategies might potentially be applied to advance 3D printing applications.</p><p id="Par13">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Cell sources for ophthalmic regeneration. The figure was created using BioRender software under an academic license</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e688" position="float" orientation="portrait" xlink:href="40135_2025_337_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title> 3D Bioprinting of Ophthalmic Tissues and Devices</title><p id="Par14">As discussed in the previous section, various 3D bioprinting options are available for different materials and cells, so that they can be used to quickly fabricate a biological prototype and become customized according to the patient&#8217;s needs. Based on the advantages, 3D bioprinting is an ideal Choice to replicate the complex microstructure of tissues. Many researchers have developed 3D bioprinted functional tissues and related devices. As Such, this section explores the 3D bioprinting of ophthalmic tissues and ophthalmic devices.</p><sec id="Sec5"><title>3D Bioprinted Ophthalmic Tissues</title><sec id="Sec6"><title>Cornea</title><p id="Par15">The cornea consists of the epithelium, stroma, endothelium, Bowman layer, and Descemet membrane. Mimicking the native cornea structure is challenging for tissue printing due to the cornea&#8217;s transparency, curvature, and layered cellular composition [<xref ref-type="bibr" rid="CR63">63</xref>]. Sorkio et al. developed a laser-assisted 3D bioprinting strategy to fabricate corneal tissue constructs using human stem cells and bioactive collagen-based hydrogels (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a) [<xref ref-type="bibr" rid="CR64">64</xref>]. In this study, collagen and two kinds of cells are used: human embryonic stem cell-derived limbal epithelial stem cells for printing epithelium-mimicking structures and human adipose tissue-derived stem cells for constructing layered stroma-mimicking structures. The printed tissues exhibit desirable mechanical properties, high cell viability, and transparency comparable to native tissues. Kim and colleagues leveraged the shear stress generated by extrusion upon 3D bioprinting, to induce the alignment of collagen fibers within a bioengineered corneal stromal construct (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b) [<xref ref-type="bibr" rid="CR65">65</xref>]. This shear-induced alignment mimics the anisotropic microstructure of the native stroma providing substantial improvements in transparency and mechanical strength. Furthermore, human corneal keratocyte precursors, which were encapsulated in cornea-derived decellularized extracellular matrix, responded favorably to the aligned matrix. This resulted in high cell viability and elongation in the fibril orientation, mimicking corneal tissue functionality. Recently, SPAAC (strain-promoted azide&#8211;alkyne cycloaddition)-based collagen bioinks have been developed for corneal reconstruction due to their rapid crosslinking under physiological conditions and excellent cytocompatibility [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. These materials demonstrate high structural integrity and precise control over microscale porosity with embedded bath printing strategies, promoting elongation and spreading of encapsulated corneal mesenchymal stromal cells. This approach holds a great potential for replicating the mechanical and structural features of the native corneal stroma in 3D bioprinted constructs as well as for developing ophthalmic drug delivery systems.</p><p id="Par16">In addition to implantable tissues, in vitro platforms better mimic the operation of the real organ with the assistance of 3D tissue printing. This can be used for customized cell studies, disease modeling, and drug development [<xref ref-type="bibr" rid="CR66">66</xref>]. For example, corneal curvature influences cell alignment. Curvature is difficult to fabricate or customize using traditional methods, but can be fabricated easily via 3D bioprinting [<xref ref-type="bibr" rid="CR67">67</xref>]. With 3D printing, an affordable and customizable corneal perfusion chamber is developed to maintain ex vivo corneal tissues in physiologically relevant conditions, enabling precise control over intraocular pressure and nutrient delivery for corneal research [<xref ref-type="bibr" rid="CR68">68</xref>]. Although specific disease models are limited in the study, the system is adaptable and holds strong potential for use in ophthalmic drug testing, disease modeling, and transplantation research.</p><p id="Par17">4D printing, which means the 3D printed model changes with stimulation, is also applied. Cell-laden tissue constructs with controllable degradation are printed by tuning the mole ratio of sodium citrate to sodium alginate [<xref ref-type="bibr" rid="CR69">69</xref>]. Human corneal epithelial cells (HCECs) encapsulated within these constructs exhibited increased proliferation rates and higher expression of cytokeratin 3 (CK3), indicating improved cellular activity with enhanced degradation. This approach assessed the impact of the 3D printed scaffold&#8217;s degradation properties on cellular behavior, aiming to optimize the bioink system for improved outcomes in tissue engineering applications.</p></sec><sec id="Sec7"><title>Retina</title><p id="Par18">The retina is a complex multi-layer tissue, responsible for collecting and processing optical signals, and then transmitting the signals to the brain for further processing. Retinal regeneration treatments are promising through use of mature photoreceptors, progenitor cells, retinal sheets and retinal pigment epithelium (RPE) cells. For regeneration, first, the photoreceptors/RPE layer organization, polarization, and alignment are critical to the functioning of the tissues. Second, cell viability must be ensured as the implantation will cause cell loss [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. 3D bioprinting has been shown to help both tissue structure and the cell viability after subretinal implantation [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par19">Extrusion-based 3D printing is used to spatially organize RPE cell spheroids within retinal constructs, mimicking the layered architecture of native retinal tissue. The printed spheroids maintained high viability, expressed characteristic RPE markers, and formed monolayer-like structures, which may serve as a promising retina model for further investigations. Masaeli et al. utilized inkjet-based bioprinting strategy to deposit matured and differentiated photoreceptors onto printed RPE layer with a thin layer of gelatin methacrylate working as Bruch&#8217;s membrane. The results showed that a functional RPE monolayer was formed with time and the microstructures are well established, which is promising to serve as an in vitro model for disease investigations [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par20">Many in vitro retina platforms are also set for investigation. Extrusion-based 3D bioprinting of bioactive basement membrane-derived dECM is used to realize monolayer RPE printing [<xref ref-type="bibr" rid="CR75">75</xref>]. 3% gelatin was optimized as a sacrificial material in the bioink to support monolayer RPE cell deposition and was finally removed after gelation, leaving a viable and well-attached RPE layer (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c). A highly functional, biomimetic in vitro outer blood-retinal barrier model was established offering superior cell compatibility, barrier integrity, and physiological relevance compared to conventional models. This model was evaluated as smoke-induced retinal pigment epithelium degeneration. A similar printing method with Human M&#252;ller glia (MIO-M1) was applied to build the MIO-M1-based retinal protection models [<xref ref-type="bibr" rid="CR76">76</xref>]. Song et al. printed temperature-sensitive, fibrin-based bioinks on a custom PLGA scaffold, imitating essential cellular architecture and interactions among RPE, endothelial cells, pericytes, and fibroblasts [<xref ref-type="bibr" rid="CR77">77</xref>]. The proposed platform emulates both key features of healthy retinal tissue and disease models such as drusen formation and choroidal neovascularization in age-related macular degeneration.</p></sec><sec id="Sec8"><title>Others</title><p id="Par21">3D printing is also very important in fabricating other ophthalmic tissues, such as orbital implants [<xref ref-type="bibr" rid="CR78">78</xref>] and intraocular lenses (IOL) [<xref ref-type="bibr" rid="CR79">79</xref>]. The combination of advanced imaging, computer-aided design, and additive manufacturing facilitates personalized surgical solutions, and improves precision and adaptability of ophthalmic implants in both structural and optical aspects.</p></sec></sec><sec id="Sec9"><title>3D Bioprinted Ophthalmic Devices</title><p id="Par22">3D bioprinting also provides more options in the field of cell-incorporated ophthalmic devices in addition to the aforementioned tissue engineering. For example, contact lenses, which directly contact tears, are considered as an excellent platform for disease diagnosis and treatment and can be customized by 3D printing. Lee et al. fabricated a micro-contoured contact lens that holds and transfers ABCB5-positive limbal stem cells onto the corneal Surface using 3D bioprinting technology (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>d) [<xref ref-type="bibr" rid="CR80">80</xref>]. The customized design and fabrication of the printed lens ensures its close attachment to the cornea and improves effective delivery and engraftment of the stem cells. This work Suggests that 3D printed contact lenses are a promising alternative to traditional autologous stem cell transplantation techniques for corneal epithelium regeneration and vision restoration in limbal stem cell deficiency.</p><p id="Par23">In addition, 3D printing offers advantages in drug delivery by increasing the complexity in terms of drug geometry to release profiles. It allows for personalized medicine preparation, including dose, drug combination, and drug-loaded implants. On-demand production by 3D printing reduces waste and facilitates targeted delivery, especially in tissues that are hard to reach. These capabilities make 3D printing a powerful method for next-generation drug formulations and individualized therapies. For example, Xu et al. 3D-printed punctal plugs for personalized ocular drug delivery (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>e) [<xref ref-type="bibr" rid="CR81">81</xref>]. Researchers evaluated cytocompatibility of the printed plugs using Balb/3T3 fibroblast cells to ensure safety for ocular applications. The results indicated that material composition significantly influences cell viability.</p><p id="Par24">Although the development of bioprinting technologies is still in the early stages, the success of replicating the microstructure and alignment of native tissues and developing personalized ophthalmic devices makes great progress in tissue recovery, which is inspiring and has the potential to be applied to other cell-based systems.</p><p id="Par25">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>3D bioprinted implants. (<bold>a</bold>) 3D bioprinted corneal tissue using human corneal keratocytes and bioactive collagen-based hydrogels. 3-day co-culture results showed a stratified, corneal progenitor marker p40 positive layer on the surface of the laser-printed structures compared to the natural cornea. Adapted from Sorkio et al. [<xref ref-type="bibr" rid="CR64">64</xref>] (<bold>b</bold>) Bioengineered cornea constructed with alignment of collagen fibrils, whose shear stress is induced from the extrusion in 3D bioprinting. Adapted from Kim et al. [<xref ref-type="bibr" rid="CR65">65</xref>] (<bold>c</bold>) Functional in vitro RPE model printed by hybrid membrane printing technology for disease investigation. Immunofluorescence images confirm the in-vitro function of the tissue in disease models. Adapted from Kim et al. [<xref ref-type="bibr" rid="CR75">75</xref>] (<bold>d</bold>) 3D-printed ABCB5-positive stem cells for corneal regeneration on contact lens. Adapted from Lee et al. [<xref ref-type="bibr" rid="CR80">80</xref>] (<bold>e</bold>) DLP 3D-printed punctal plugs and its cumulative drug release profile. Adapted from Xu et al. [<xref ref-type="bibr" rid="CR81">81</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e846" position="float" orientation="portrait" xlink:href="40135_2025_337_Fig3_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec10"><title>Encapsulated Cell Therapy and Applications for 3D Printing</title><p id="Par26">In this section, we explore ophthalmic therapeutic system with ECT and applications of 3D bioprinting. ECT was proposed in the 1960&#8201;s [<xref ref-type="bibr" rid="CR82">82</xref>]and has since been adapted for use throughout the body. ECT involves using cells to produce therapeutic factors which are released into their local environment. To prevent rejection of the cells, implanted cells are encapsulated within a semi-permeable barrier that allows nutrients and oxygen to reach the cells while shielding them from immune attack. These cells may be allogeneic cells Such as encapsulated pancreatic cells that respond to local glucose levels to provide insulin in type 1 diabetics [<xref ref-type="bibr" rid="CR83">83</xref>]. They may also be transgenic cell lines which are used to produce specific protein therapeutics to treat disease.</p><p id="Par27">Both macroencapsulation and microencapsulation have been evaluated in ECT. Macroencapsulation involves construction of an engineered device, with an internal cell supportive scaffold that is enclosed with an immunoprotective membrane. Cells suspended in culture medium or buffer are loaded into the device, which is then sealed [<xref ref-type="bibr" rid="CR84">84</xref>]. Suture clips may be used to fasten the device during implantation. This provides a structural advantage for implantation and the engineered implant materials can offer longevity of over a decade [<xref ref-type="bibr" rid="CR85">85</xref>]. Macroencapsulated ARPE-19 cells have delivered soluble vascular endothelial growth factor receptor [<xref ref-type="bibr" rid="CR86">86</xref>]ciliary neurotrophic factor (CNTF) [<xref ref-type="bibr" rid="CR87">87</xref>&#8211;<xref ref-type="bibr" rid="CR91">91</xref>] and brain-derived neurotrophic factor (BDNF) [<xref ref-type="bibr" rid="CR92">92</xref>]. The first ECT was approved by the FDA in March 2025 and is a macroencapsulated device for treatment of macular telangiectasia type-2.</p><p id="Par28">Microencapsulation consists of immobilizing groups of cells within a polymeric semi-permeable membrane. This leads to an increased surface area to volume compared with macroencapsulation, which may be beneficial for cellular transport. ARPE-19 cells microencapsulated in sodium alginate have delivered a complement receptor-2 fragment linked to the inhibitory domain of factor H (CR2-fH) [<xref ref-type="bibr" rid="CR93">93</xref>]. Murine myoblasts microencapsulated in alginate-poly-l-lysine-alginate have delivered vascular endothelial growth factor soluble receptor-2 [<xref ref-type="bibr" rid="CR94">94</xref>]. HEK293 cells microencapsulated in a composite collagen-alginate scaffold have delivered glial cell line-derived neurotrophic factor (GDNF) [<xref ref-type="bibr" rid="CR95">95</xref>]. Further, soluble vascular endothelial growth factor receptor secreting ARPE-19 cells were encapsulated in hydrogel, which may be directly injected or used as the matrix for a macroencapsulated device [<xref ref-type="bibr" rid="CR96">96</xref>].</p><p id="Par29">3D printing has been used to assist manufacturing for this regenerative medicine-based drug delivery device. Traditional macroencapsulation fabrication has involved assembly of thin fibers for the supportive cell scaffold, with an outer semipermeable membrane and sealed capsule. Advances in additive manufacturing may be used to increase flexibility and reduce fabrication time for ECT.</p><p id="Par30">Kojima et al. developed a 3D printed macroencapsulated device for delivery of BDNF. The device is meant to be placed adjacent to the sclera, in the subconjunctival, subtenon, retrobulbar, or peribulbar space and allow for trans-scleral drug delivery. This device consists of a cylindrical reservoir with a glued-on cap and is filled with ARPE-19 cells cultured on collagen coated polystyrene sheets. A semipermeable membrane that allows nutrients to reach the cells and allows diffusion of BDNF is located on the side of the reservoir facing the sclera. Polyethylene glycol dimethylacrylate (PEGDM) was chosen for the semipermeable membrane as it was shown to significantly reduce IGG permeability while allowing smaller molecules of 40&#160;kDa and less to more freely diffuse. The cap and walls of the device were fabricated using triethylene glycol dimethacrylate (TEGDM) and bonded together using PEGDM. For 3D printing, resins were fabricated from PEGDM and TEGFM using photoinitiator and photosensitizers. The resins were printed using a QiDi Tech Shadow 5.5&#160;s with 50-&#181;m thickness layers. To allow a multi-material print, the TEGDM resin was used to print the first layer, followed by washing the build plate and printing of the semi porous PEGDM layer. Once this was complete, the build plate was washed again and the TEGDM resin was used to complete the reservoir [<xref ref-type="bibr" rid="CR92">92</xref>]. Using 3D printing shortened fabrication time by 4&#8211;5 times and has the potential to build complex ECT devices that are not buildable using traditional techniques.</p><p id="Par31">ECT shows promise for regenerative drug delivery to the eye. Not only is the eye the first location where ECT has been approved in the body, but there are many other ocular diseases which may be treated using cell-based therapeutic delivery. The eye is especially amenable to ECT given it is an immune privileged site, there is a large precedence of safely implanting medical devices into the eye, and the clinician&#8217;s ability to directly monitor the implanted device. ECT has the potential to provide long-term drug delivery for periods of time much longer than bioerodible or reservoir-based, extended drug delivery systems. Unlike current gene therapy systems, ECT is reversible by surgical removal of the device [<xref ref-type="bibr" rid="CR85">85</xref>]. Further, ECT may not have the inflammatory limitations that have been seen by current gene therapies [<xref ref-type="bibr" rid="CR97">97</xref>]. However, ECT devices require surgical implantation, with the risks of the surgery and post-operative complications of an implanted device [<xref ref-type="bibr" rid="CR98">98</xref>]. Further, the cells need to be able to deliver a therapeutic amount of pharmaceutical over time [<xref ref-type="bibr" rid="CR99">99</xref>]. 3D printing has shown promise for the fabrication of future ECT due to flexibility in manufacturing complex structures, the ability to incorporate multiple materials into a device, and increased throughput of 3D printing.</p></sec><sec id="Sec11"><title>Future Direction</title><p id="Par32">Recent advances of cell therapy and 3D bioprinting technology in ophthalmology have shown great potential in tissue engineering and regenerative medicine. However, there exist several regulatory and technical hurdles. The FDA has established guidelines for 3D-printed medical devices since 2017 [<xref ref-type="bibr" rid="CR100">100</xref>], however, comprehensive regulations for 3D-printed therapeutic systems remain underdeveloped. To bridge the current research from innovative to clinical and practical applications, it is important to establish robust quality standards and evaluation protocols for 3D-printed therapeutic systems. Once regulatory issues are addressed, the field of cell therapy, 3D bioprinting technology, and their combinations will likely increase applicability in clinical settings, particularly for personalized treatment approaches. To do so, cellular functionality will be enhanced, Such as the development of cells capable of detecting physiological Changes and modulating the secretion of therapeutic molecules. To apply these responsive cells, cellular reservoir-containing implants need to be designed not to impede cellular function. Furthermore, from a systems perspective, upgrading bioprinting technologies to incorporate biomaterials with diagnostic and therapeutic capabilities would be necessary. Therefore, a thorough and interdisciplinary effort is needed to explore innovative manufacturing techniques alongside advancements in cell engineering. By pursuing these parallel research avenues, we can pave the way for the development of sophisticated 3D bioprinted cellular therapeutic systems tailored for ophthalmic applications.</p></sec><sec id="Sec12"><title>Key References</title><p id="Par33">
<list list-type="bullet"><list-item><p id="Par34">Brunel, L. G. et al. Embedded 3D bioprinting of collagen inks into microgel baths to control hydrogel microstructure and cell spreading. Advanced healthcare materials <bold>13</bold>, 2303325 (2024).<list list-type="bullet"><list-item><p id="Par35">This study presented that embedded 3D bioprinting with microgel support baths enables precise control over collagen hydrogel microstructure and cell spreading. By incorporating SPAAC crosslinking, the printed constructs achieve both mechanical stability and cellular functionality, showing strong potential for corneal tissue reconstruction.</p></list-item></list></p></list-item><list-item><p id="Par36">Xiao, Y., McGhee, C. N. &amp; Zhang, J. Adult stem cells in the eye: Identification, characterisations, and therapeutic application in ocular regeneration&#8211;A review. <italic toggle="yes">Clinical &amp; Experimental Ophthalmology</italic>
<bold>52</bold>, 148-166 (2024).<list list-type="bullet"><list-item><p id="Par37">This review highlights the use of various stem cells in ocular regeneration, emphasizing adult stem cells and their therapeutic potential, while addressing key challenges like integration, immune compatibility, and long-term stability.</p></list-item></list></p></list-item><list-item><p id="Par38">Hoseinzadeh, A. et al. Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights. <italic toggle="yes">Stem Cell Research &amp; Therapy</italic>
<bold>16</bold>, 33 (2025).<list list-type="bullet"><list-item><p id="Par39">This study highlights a promising approach of co-incorporating mesenchymal stem cells (MSCs) to address challenges in therapeutic cell delivery. It shifts from direct engraftment to immune modulation via apoptotic body uptake as mechanism behind MSCs&#8217; therapeutic effects in bioprinted constructs.</p></list-item></list></p></list-item><list-item><p id="Par40">Chew, E. Y. et al. Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2. NEJM evidence <bold>4</bold>, EVIDoa2400481 (2025).<list list-type="bullet"><list-item><p id="Par41">This is the most recent paper from the only FDA approved encapsulated cell therapy device. The paper presents the results from the two phase 3 clinical trials and discusses longevity of encapsulated cell therapy of at least 14.5 years.</p></list-item></list></p></list-item><list-item><p id="Par42">Bhise, M. G., Patel, L. &amp; Patel, K. 3D Printed Medical Devices: Regulatory Standards and Technological Advancements in the USA, Canada and Singapore-A Cross-National Study. <italic toggle="yes">International Journal of Pharmaceutical Investigation</italic>
<bold>14</bold> (2024).<list list-type="bullet"><list-item><p id="Par43">This study presents a concise overview of 3D printed medical devices and the related regulatory. It highlights high demands of bioprinting-related regulatory to expand creating and implementing patient-specific solutions.</p></list-item></list></p></list-item></list>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by an unrestricted grant from the Research to Prevent Blindness and NIH grant P30-EY026877. C.D. is supported by the NIH K08EY036955, the Robert Machemer Foundation, the E. Matilda Ziegler Foundation, and Alcon Research Institute.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>H.K. developed the outline for the manuscript. H.K., G.N., W.H., and C.D. wrote the main manuscript. W.H. and G.N. prepared figures. V.M. helped with the concept of the manuscript. All authors reviewed and helped with revisions of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Human and Animal Rights and Informed Consent</title><p id="Par44">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing Interests</title><p id="Par45">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajekiigbe</surname><given-names>VO</given-names></name><etal/></person-group><article-title>Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology</article-title><source>Int Ophthalmol</source><year>2025</year><volume>45</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.1007/s10792-025-03493-7</pub-id><pub-id pub-id-type="pmid">40120030</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ajekiigbe VO, et al. Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology. Int Ophthalmol. 2025;45:113.<pub-id pub-id-type="pmid">40120030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10792-025-03493-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajgaonkar</surname><given-names>BS</given-names></name><name name-style="western"><surname>Kumaran</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Jain</surname><given-names>RD</given-names></name><name name-style="western"><surname>Dandekar</surname><given-names>PP</given-names></name></person-group><article-title>Cell-based therapies for corneal and retinal disorders</article-title><source>Stem Cell Rev Rep</source><year>2023</year><volume>19</volume><fpage>2650</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s12015-023-10623-0</pub-id><pub-id pub-id-type="pmid">37704835</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ajgaonkar BS, Kumaran A, Kumar S, Jain RD, Dandekar PP. Cell-based therapies for corneal and retinal disorders. Stem Cell Rev Rep. 2023;19:2650&#8211;82.<pub-id pub-id-type="pmid">37704835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12015-023-10623-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aharony</surname><given-names>I</given-names></name><name name-style="western"><surname>Michowiz</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldenberg-Cohen</surname><given-names>N</given-names></name></person-group><article-title>The promise of stem cell-based therapeutics in ophthalmology</article-title><source>Neural Regen Res</source><year>2017</year><volume>12</volume><fpage>173</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.200793</pub-id><pub-id pub-id-type="pmid">28400789</pub-id><pub-id pub-id-type="pmcid">PMC5361491</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Aharony I, Michowiz S, Goldenberg-Cohen N. The promise of stem cell-based therapeutics in ophthalmology. Neural Regen Res. 2017;12:173&#8211;80.<pub-id pub-id-type="pmid">28400789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.200793</pub-id><pub-id pub-id-type="pmcid">PMC5361491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinkle</surname><given-names>JW</given-names></name><name name-style="western"><surname>Mahmoudzadeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Kuriyan</surname><given-names>AE</given-names></name></person-group><article-title>Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer cell therapy clinics</article-title><source>Stem Cell Res Ther</source><year>2021</year><volume>12</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s13287-021-02546-9</pub-id><pub-id pub-id-type="pmid">34635174</pub-id><pub-id pub-id-type="pmcid">PMC8504041</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer cell therapy clinics. Stem Cell Res Ther. 2021;12:1&#8211;9.<pub-id pub-id-type="pmid">34635174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-021-02546-9</pub-id><pub-id pub-id-type="pmcid">PMC8504041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farasati Far</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hydrogel encapsulation techniques and its clinical applications in drug delivery and regenerative medicine: a systematic review</article-title><source>ACS Omega</source><year>2024</year><volume>9</volume><fpage>29139</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c10102</pub-id><pub-id pub-id-type="pmid">39005800</pub-id><pub-id pub-id-type="pmcid">PMC11238230</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Farasati Far B, et al. Hydrogel encapsulation techniques and its clinical applications in drug delivery and regenerative medicine: a systematic review. ACS Omega. 2024;9:29139&#8211;58.<pub-id pub-id-type="pmid">39005800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsomega.3c10102</pub-id><pub-id pub-id-type="pmcid">PMC11238230</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acarregui</surname><given-names>A</given-names></name><etal/></person-group><article-title>Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response</article-title><source>Acta Biomater</source><year>2014</year><volume>10</volume><fpage>4206</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2014.06.038</pub-id><pub-id pub-id-type="pmid">25010523</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Acarregui A, et al. Multifunctional hydrogel-based scaffold for improving the functionality of encapsulated therapeutic cells and reducing inflammatory response. Acta Biomater. 2014;10:4206&#8211;16.<pub-id pub-id-type="pmid">25010523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2014.06.038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Bio-orthogonal crosslinking and hyaluronan facilitate transparent healing after treatment of deep corneal injuries with in situ-forming hydrogels</article-title><source>NPJ Regen Med</source><year>2025</year><volume>10</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1038/s41536-024-00385-9</pub-id><pub-id pub-id-type="pmid">39905045</pub-id><pub-id pub-id-type="pmcid">PMC11794660</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chen F, et al. Bio-orthogonal crosslinking and hyaluronan facilitate transparent healing after treatment of deep corneal injuries with in situ-forming hydrogels. NPJ Regen Med. 2025;10:8.<pub-id pub-id-type="pmid">39905045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41536-024-00385-9</pub-id><pub-id pub-id-type="pmcid">PMC11794660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barar</surname><given-names>J</given-names></name><name name-style="western"><surname>Aghanejad</surname><given-names>A</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>M</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y</given-names></name></person-group><article-title>Advanced drug delivery and targeting technologies for the ocular diseases</article-title><source>BioImpacts: BI</source><year>2016</year><volume>6</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.15171/bi.2016.07</pub-id><pub-id pub-id-type="pmid">27340624</pub-id><pub-id pub-id-type="pmcid">PMC4916551</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery and targeting technologies for the ocular diseases. BioImpacts: BI. 2016;6:49.<pub-id pub-id-type="pmid">27340624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15171/bi.2016.07</pub-id><pub-id pub-id-type="pmcid">PMC4916551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>H-G</given-names></name><etal/></person-group><article-title>Application of 3D bioprinting in the prevention and the therapy for human diseases</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><fpage>177</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00566-8</pub-id><pub-id pub-id-type="pmid">33986257</pub-id><pub-id pub-id-type="pmcid">PMC8119699</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yi H-G, et al. Application of 3D bioprinting in the prevention and the therapy for human diseases. Signal Transduct Target Ther. 2021;6:177.<pub-id pub-id-type="pmid">33986257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00566-8</pub-id><pub-id pub-id-type="pmcid">PMC8119699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>G</given-names></name><etal/></person-group><article-title>3D printing in ophthalmology: from medical implants to personalised medicine</article-title><source>Int J Pharm</source><year>2022</year><volume>625</volume><fpage>122094</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122094</pub-id><pub-id pub-id-type="pmid">35952803</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Tan G, et al. 3D printing in ophthalmology: from medical implants to personalised medicine. Int J Pharm. 2022;625:122094.<pub-id pub-id-type="pmid">35952803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2022.122094</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>U</given-names></name><etal/></person-group><article-title>The emerging role of 3D-printing in ocular drug delivery: challenges, current status, and future prospects</article-title><source>J Drug Deliv Sci Technol</source><year>2022</year><volume>76</volume><fpage>103798</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2022.103798</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Garg U, et al. The emerging role of 3D-printing in ocular drug delivery: challenges, current status, and future prospects. J Drug Deliv Sci Technol. 2022;76:103798.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsui</surname><given-names>JK</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S</given-names></name><name name-style="western"><surname>da Cruz</surname><given-names>L</given-names></name><name name-style="western"><surname>Dick</surname><given-names>AD</given-names></name><name name-style="western"><surname>Sagoo</surname><given-names>MS</given-names></name></person-group><article-title>Applications of three-dimensional printing in ophthalmology</article-title><source>Surv Ophthalmol</source><year>2022</year><volume>67</volume><fpage>1287</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2022.01.004</pub-id><pub-id pub-id-type="pmid">35085588</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Tsui JK, Bell S, da Cruz L, Dick AD, Sagoo MS. Applications of three-dimensional printing in ophthalmology. Surv Ophthalmol. 2022;67:1287&#8211;310.<pub-id pub-id-type="pmid">35085588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.survophthal.2022.01.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bom</surname><given-names>S</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>R</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>HM</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C</given-names></name><name name-style="western"><surname>Marto</surname><given-names>J</given-names></name></person-group><article-title>On the progress of hydrogel-based 3D printing: correlating rheological properties with printing behaviour</article-title><source>Int J Pharm</source><year>2022</year><volume>615</volume><fpage>121506</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121506</pub-id><pub-id pub-id-type="pmid">35085727</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bom S, Ribeiro R, Ribeiro HM, Santos C, Marto J. On the progress of hydrogel-based 3D printing: correlating rheological properties with printing behaviour. Int J Pharm. 2022;615:121506.<pub-id pub-id-type="pmid">35085727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2022.121506</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCormack</surname><given-names>A</given-names></name><name name-style="western"><surname>Highley</surname><given-names>CB</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>NR</given-names></name><name name-style="western"><surname>Melchels</surname><given-names>FP</given-names></name></person-group><article-title>3D printing in suspension baths: keeping the promises of bioprinting afloat</article-title><source>Trends Biotechnol</source><year>2020</year><volume>38</volume><fpage>584</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2019.12.020</pub-id><pub-id pub-id-type="pmid">31955894</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">McCormack A, Highley CB, Leslie NR, Melchels FP. 3D printing in suspension baths: keeping the promises of bioprinting afloat. Trends Biotechnol. 2020;38:584&#8211;93.<pub-id pub-id-type="pmid">31955894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2019.12.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>SM</given-names></name><etal/></person-group><article-title>3D Bioprinting using universal orthogonal network (UNION) Bioinks</article-title><source>Adv Funct Mater</source><year>2021</year><volume>31</volume><fpage>2007983</fpage><pub-id pub-id-type="doi">10.1002/adfm.202007983</pub-id><pub-id pub-id-type="pmid">33613150</pub-id><pub-id pub-id-type="pmcid">PMC7888563</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hull SM, et al. 3D Bioprinting using universal orthogonal network (UNION) Bioinks. Adv Funct Mater. 2021;31:2007983.<pub-id pub-id-type="pmid">33613150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.202007983</pub-id><pub-id pub-id-type="pmcid">PMC7888563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunel</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Embedded 3D Bioprinting of collagen inks into microgel baths to control hydrogel microstructure and cell spreading</article-title><source>Adv Healthc Mater</source><year>2024</year><volume>13</volume><fpage>2303325</fpage><pub-id pub-id-type="doi">10.1002/adhm.202303325</pub-id><pub-id pub-id-type="pmcid">PMC11192865</pub-id><pub-id pub-id-type="pmid">38134346</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Brunel LG, et al. Embedded 3D Bioprinting of collagen inks into microgel baths to control hydrogel microstructure and cell spreading. Adv Healthc Mater. 2024;13:2303325.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202303325</pub-id><pub-id pub-id-type="pmcid">PMC11192865</pub-id><pub-id pub-id-type="pmid">38134346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurkovi&#263;</surname><given-names>JS</given-names></name><name name-style="western"><surname>Vojinovi&#263;</surname><given-names>R</given-names></name><name name-style="western"><surname>Doli&#263;anin</surname><given-names>Z</given-names></name></person-group><article-title>Corneal Stem Cells as a Source of Regenerative Cell-Based Therapy.</article-title><source>Stem Cells Int</source><year>2020</year><volume>2020</volume><fpage>8813447</fpage><pub-id pub-id-type="doi">10.1155/2020/8813447</pub-id><pub-id pub-id-type="pmid">32765614</pub-id><pub-id pub-id-type="pmcid">PMC7388005</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nurkovi&#263; JS, Vojinovi&#263; R, Doli&#263;anin Z. Corneal Stem Cells as a Source of Regenerative Cell-Based Therapy. Stem Cells Int. 2020;2020:8813447.<pub-id pub-id-type="pmid">32765614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8813447</pub-id><pub-id pub-id-type="pmcid">PMC7388005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klymenko</surname><given-names>V</given-names></name><name name-style="western"><surname>Gonz&#225;lez Mart&#237;nez</surname><given-names>OG</given-names></name><name name-style="western"><surname>Zarbin</surname><given-names>M</given-names></name></person-group><article-title>Recent progress in retinal pigment epithelium cell-based therapy for retinal disease</article-title><source>Stem Cells Transl Med</source><year>2024</year><volume>13</volume><fpage>317</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1093/stcltm/szae004</pub-id><pub-id pub-id-type="pmid">38394392</pub-id><pub-id pub-id-type="pmcid">PMC11016854</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Klymenko V, Gonz&#225;lez Mart&#237;nez OG, Zarbin M. Recent progress in retinal pigment epithelium cell-based therapy for retinal disease. Stem Cells Transl Med. 2024;13:317&#8211;31.<pub-id pub-id-type="pmid">38394392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/stcltm/szae004</pub-id><pub-id pub-id-type="pmcid">PMC11016854</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klymenko</surname><given-names>V</given-names></name><name name-style="western"><surname>Gonz&#225;lez Mart&#237;nez</surname><given-names>OG</given-names></name><name name-style="western"><surname>Zarbin</surname><given-names>MA</given-names></name></person-group><article-title>Recent progress in photoreceptor cell-based therapy for degenerative retinal disease</article-title><source>Stem Cells Transl Med</source><year>2024</year><volume>13</volume><fpage>332</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1093/stcltm/szae005</pub-id><pub-id pub-id-type="pmid">38417110</pub-id><pub-id pub-id-type="pmcid">PMC11016853</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Klymenko V, Gonz&#225;lez Mart&#237;nez OG, Zarbin MA. Recent progress in photoreceptor cell-based therapy for degenerative retinal disease. Stem Cells Transl Med. 2024;13:332&#8211;45.<pub-id pub-id-type="pmid">38417110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/stcltm/szae005</pub-id><pub-id pub-id-type="pmcid">PMC11016853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>McGhee</surname><given-names>CN</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Adult stem cells in the eye: identification, characterisation, and therapeutic application in ocular regeneration&#8211;A review</article-title><source>Clin Exp Ophthalmol</source><year>2024</year><volume>52</volume><fpage>148</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1111/ceo.14309</pub-id><pub-id pub-id-type="pmid">38214071</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Xiao Y, McGhee CN, Zhang J. Adult stem cells in the eye: identification, characterisation, and therapeutic application in ocular regeneration&#8211;A review. Clin Exp Ophthalmol. 2024;52:148&#8211;66.<pub-id pub-id-type="pmid">38214071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ceo.14309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulon</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>A novel glaucoma approach: stem cell regeneration of the trabecular meshwork</article-title><source>Prog Retin Eye Res</source><year>2022</year><volume>90</volume><fpage>101063</fpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2022.101063</pub-id><pub-id pub-id-type="pmid">35398015</pub-id><pub-id pub-id-type="pmcid">PMC9464663</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Coulon SJ, et al. A novel glaucoma approach: stem cell regeneration of the trabecular meshwork. Prog Retin Eye Res. 2022;90:101063.<pub-id pub-id-type="pmid">35398015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preteyeres.2022.101063</pub-id><pub-id pub-id-type="pmcid">PMC9464663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volarevic</surname><given-names>V</given-names></name><etal/></person-group><article-title>Ethical and safety issues of stem cell-based therapy</article-title><source>Int J Med Sci</source><year>2018</year><volume>15</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.7150/ijms.21666</pub-id><pub-id pub-id-type="pmid">29333086</pub-id><pub-id pub-id-type="pmcid">PMC5765738</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Volarevic V, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15:36.<pub-id pub-id-type="pmid">29333086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.21666</pub-id><pub-id pub-id-type="pmcid">PMC5765738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittenger</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Mesenchymal stem cell perspective: cell biology to clinical progress</article-title><source>NPJ Regen Med</source><year>2019</year><volume>4</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1038/s41536-019-0083-6</pub-id><pub-id pub-id-type="pmid">31815001</pub-id><pub-id pub-id-type="pmcid">PMC6889290</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Pittenger MF, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22.<pub-id pub-id-type="pmid">31815001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41536-019-0083-6</pub-id><pub-id pub-id-type="pmcid">PMC6889290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luque-Campos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>798</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00798</pub-id><pub-id pub-id-type="pmid">31040848</pub-id><pub-id pub-id-type="pmcid">PMC6477064</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Luque-Campos N, et al. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Front Immunol. 2019;10:798.<pub-id pub-id-type="pmid">31040848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00798</pub-id><pub-id pub-id-type="pmcid">PMC6477064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noronha</surname><given-names>NdC</given-names></name><etal/></person-group><article-title>Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies</article-title><source>Stem Cell Res Ther</source><year>2019</year><volume>10</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">31046833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-019-1224-y</pub-id><pub-id pub-id-type="pmcid">PMC6498654</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Noronha NdC, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10:1&#8211;21.<pub-id pub-id-type="pmid">31046833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-019-1224-y</pub-id><pub-id pub-id-type="pmcid">PMC6498654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarsenova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1010399</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1010399</pub-id><pub-id pub-id-type="pmid">36211399</pub-id><pub-id pub-id-type="pmcid">PMC9537745</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Sarsenova M, et al. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells. Front Immunol. 2022;13:1010399.<pub-id pub-id-type="pmid">36211399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1010399</pub-id><pub-id pub-id-type="pmcid">PMC9537745</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contreras-Lopez</surname><given-names>R</given-names></name><etal/></person-group><article-title>The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>445</fpage><pub-id pub-id-type="doi">10.7150/thno.51631</pub-id><pub-id pub-id-type="pmid">33391485</pub-id><pub-id pub-id-type="pmcid">PMC7681096</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Contreras-Lopez R, et al. The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential. Theranostics. 2021;11:445.<pub-id pub-id-type="pmid">33391485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.51631</pub-id><pub-id pub-id-type="pmcid">PMC7681096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>JV</given-names></name><etal/></person-group><article-title>Cultivation and characterization of oral mucosal epithelial cells on fibrin gel in a xenobiotic-free medium for the treatment of limbal stem cell deficiency</article-title><source>Exp Eye Res</source><year>2025</year><volume>253</volume><fpage>110300</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2025.110300</pub-id><pub-id pub-id-type="pmid">39978745</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cabral JV, et al. Cultivation and characterization of oral mucosal epithelial cells on fibrin gel in a xenobiotic-free medium for the treatment of limbal stem cell deficiency. Exp Eye Res. 2025;253:110300.<pub-id pub-id-type="pmid">39978745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2025.110300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurkunas</surname><given-names>UV</given-names></name><etal/></person-group><article-title>Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the US</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><fpage>1607</fpage><pub-id pub-id-type="doi">10.1038/s41467-025-56461-1</pub-id><pub-id pub-id-type="pmid">40038272</pub-id><pub-id pub-id-type="pmcid">PMC11880323</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Jurkunas UV, et al. Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the US. Nat Commun. 2025;16:1607.<pub-id pub-id-type="pmid">40038272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-56461-1</pub-id><pub-id pub-id-type="pmcid">PMC11880323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitazawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Donor corneal endothelial cell maturity and its impact on graft survival in glaucoma patients undergoing corneal transplantation</article-title><source>Am J Ophthalmol</source><year>2024</year><volume>262</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2024.01.033</pub-id><pub-id pub-id-type="pmid">38307212</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kitazawa K, et al. Donor corneal endothelial cell maturity and its impact on graft survival in glaucoma patients undergoing corneal transplantation. Am J Ophthalmol. 2024;262:1&#8211;9.<pub-id pub-id-type="pmid">38307212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajo.2024.01.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treumer</surname><given-names>F</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>A</given-names></name><name name-style="western"><surname>Klatt</surname><given-names>C</given-names></name><name name-style="western"><surname>Roider</surname><given-names>J</given-names></name></person-group><article-title>Autologous retinal pigment epithelium&#8211;choroid sheet transplantation in age related macular degeneration: morphological and functional results</article-title><source>Br J Ophthalmol</source><year>2007</year><volume>91</volume><fpage>349</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/bjo.2006.102152</pub-id><pub-id pub-id-type="pmid">17035275</pub-id><pub-id pub-id-type="pmcid">PMC1857678</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Treumer F, Bunse A, Klatt C, Roider J. Autologous retinal pigment epithelium&#8211;choroid sheet transplantation in age related macular degeneration: morphological and functional results. Br J Ophthalmol. 2007;91:349&#8211;53.<pub-id pub-id-type="pmid">17035275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.2006.102152</pub-id><pub-id pub-id-type="pmcid">PMC1857678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humayun</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Long-term follow-up of a phase 1/2a clinical trial of a stem cell-derived bioengineered retinal pigment epithelium implant for geographic atrophy</article-title><source>Ophthalmology</source><year>2024</year><volume>131</volume><fpage>682</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2023.12.028</pub-id><pub-id pub-id-type="pmid">38160882</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Humayun MS, et al. Long-term follow-up of a phase 1/2a clinical trial of a stem cell-derived bioengineered retinal pigment epithelium implant for geographic atrophy. Ophthalmology. 2024;131:682&#8211;91.<pub-id pub-id-type="pmid">38160882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2023.12.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Genome editing in the treatment of ocular diseases</article-title><source>Exp Mol Med</source><year>2023</year><volume>55</volume><fpage>1678</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s12276-023-01057-2</pub-id><pub-id pub-id-type="pmid">37524870</pub-id><pub-id pub-id-type="pmcid">PMC10474087</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Choi EH, et al. Genome editing in the treatment of ocular diseases. Exp Mol Med. 2023;55:1678&#8211;90.<pub-id pub-id-type="pmid">37524870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-023-01057-2</pub-id><pub-id pub-id-type="pmcid">PMC10474087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names>S</given-names></name><etal/></person-group><article-title>A genetic modification that reduces ON-bipolar cells in hESC-derived retinas enhances functional integration after transplantation</article-title><source>IScience</source><year>2022</year><pub-id pub-id-type="doi">10.1016/j.isci.2021.103657</pub-id><pub-id pub-id-type="pmid">35024589</pub-id><pub-id pub-id-type="pmcid">PMC8733179</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yamasaki S, et al. A genetic modification that reduces ON-bipolar cells in hESC-derived retinas enhances functional integration after transplantation. iScience 2022;25:103657. 10.1016/j.isci.2021.103657<pub-id pub-id-type="pmid">35024589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.103657</pub-id><pub-id pub-id-type="pmcid">PMC8733179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Corneal regeneration using gene therapy approaches</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>1280</fpage><pub-id pub-id-type="doi">10.3390/cells12091280</pub-id><pub-id pub-id-type="pmid">37174680</pub-id><pub-id pub-id-type="pmcid">PMC10177166</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Sarkar S, et al. Corneal regeneration using gene therapy approaches. Cells. 2023;12:1280.<pub-id pub-id-type="pmid">37174680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12091280</pub-id><pub-id pub-id-type="pmcid">PMC10177166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>MI</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YL</given-names></name></person-group><article-title>Genetic modification of stem cells for transplantation</article-title><source>Adv Drug Deliv Rev</source><year>2008</year><volume>60</volume><fpage>160</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2007.08.035</pub-id><pub-id pub-id-type="pmid">18031863</pub-id><pub-id pub-id-type="pmcid">PMC2734411</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Phillips MI, Tang YL. Genetic modification of stem cells for transplantation. Adv Drug Deliv Rev. 2008;60:160&#8211;72.<pub-id pub-id-type="pmid">18031863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2007.08.035</pub-id><pub-id pub-id-type="pmcid">PMC2734411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fouladi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Safety and efficacy of OXB-202, a genetically engineered tissue therapy for the prevention of rejection in high-risk corneal transplant patients</article-title><source>Hum Gene Ther</source><year>2018</year><volume>29</volume><fpage>687</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1089/hum.2017.184</pub-id><pub-id pub-id-type="pmid">29361840</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Fouladi N, et al. Safety and efficacy of OXB-202, a genetically engineered tissue therapy for the prevention of rejection in high-risk corneal transplant patients. Hum Gene Ther. 2018;29:687&#8211;98.<pub-id pub-id-type="pmid">29361840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2017.184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaitsuka</surname><given-names>T</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>F</given-names></name></person-group><article-title>Response of pluripotent stem cells to environmental stress and its application for directed differentiation</article-title><source>Biology</source><year>2021</year><volume>10</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.3390/biology10020084</pub-id><pub-id pub-id-type="pmid">33498611</pub-id><pub-id pub-id-type="pmcid">PMC7912122</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kaitsuka T, Hakim F. Response of pluripotent stem cells to environmental stress and its application for directed differentiation. Biology. 2021;10:84.<pub-id pub-id-type="pmid">33498611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology10020084</pub-id><pub-id pub-id-type="pmcid">PMC7912122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busch</surname><given-names>R</given-names></name><etal/></person-group><article-title>Regulation of the endothelial apelin/apj system by hemodynamic fluid flow</article-title><source>Cell Signal</source><year>2015</year><volume>27</volume><fpage>1286</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.03.011</pub-id><pub-id pub-id-type="pmid">25817266</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Busch R, et al. Regulation of the endothelial apelin/apj system by hemodynamic fluid flow. Cell Signal. 2015;27:1286&#8211;96.<pub-id pub-id-type="pmid">25817266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2015.03.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reina-Romo</surname><given-names>E</given-names></name><etal/></person-group><article-title>Towards the experimentally-informed in silico nozzle design optimization for extrusion-based bioprinting of shear-thinning hydrogels</article-title><source>Front Bioeng Biotechnol</source><year>2021</year><volume>9</volume><fpage>701778</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2021.701778</pub-id><pub-id pub-id-type="pmid">34422780</pub-id><pub-id pub-id-type="pmcid">PMC8378215</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Reina-Romo E, et al. Towards the experimentally-informed in silico nozzle design optimization for extrusion-based bioprinting of shear-thinning hydrogels. Front Bioeng Biotechnol. 2021;9:701778.<pub-id pub-id-type="pmid">34422780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2021.701778</pub-id><pub-id pub-id-type="pmcid">PMC8378215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrocinio</surname><given-names>D</given-names></name><etal/></person-group><article-title>Biopolymers for tissue engineering: crosslinking, printing techniques, and applications</article-title><source>Gels</source><year>2023</year><volume>9</volume><fpage>890</fpage><pub-id pub-id-type="doi">10.3390/gels9110890</pub-id><pub-id pub-id-type="pmid">37998980</pub-id><pub-id pub-id-type="pmcid">PMC10670821</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Patrocinio D, et al. Biopolymers for tissue engineering: crosslinking, printing techniques, and applications. Gels. 2023;9:890.<pub-id pub-id-type="pmid">37998980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/gels9110890</pub-id><pub-id pub-id-type="pmcid">PMC10670821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Application prospect and preliminary exploration of GelMA in corneal stroma regeneration</article-title><source>Polymers</source><year>2022</year><volume>14</volume><fpage>4227</fpage><pub-id pub-id-type="doi">10.3390/polym14194227</pub-id><pub-id pub-id-type="pmid">36236174</pub-id><pub-id pub-id-type="pmcid">PMC9571618</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Su G, Li G, Wang W, Xu L. Application prospect and preliminary exploration of GelMA in corneal stroma regeneration. Polymers. 2022;14:4227.<pub-id pub-id-type="pmid">36236174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/polym14194227</pub-id><pub-id pub-id-type="pmcid">PMC9571618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vashist</surname><given-names>A</given-names></name><name name-style="western"><surname>Vashist</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Recent advances in hydrogel based drug delivery systems for the human body</article-title><source>J Mater Chem B</source><year>2014</year><volume>2</volume><fpage>147</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1039/C3TB21016B</pub-id><pub-id pub-id-type="pmid">32261602</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Vashist A, Vashist A, Gupta Y, Ahmad S. Recent advances in hydrogel based drug delivery systems for the human body. J Mater Chem B. 2014;2:147&#8211;66.<pub-id pub-id-type="pmid">32261602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c3tb21016b</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>P</given-names></name><etal/></person-group><article-title>Kuragel: a biomimetic hydrogel scaffold designed to promote corneal regeneration</article-title><source>iScience</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.isci.2024.109641</pub-id><pub-id pub-id-type="pmid">38646166</pub-id><pub-id pub-id-type="pmcid">PMC11031829</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Agrawal P, et al. Kuragel: A biomimetic hydrogel scaffold designed to promote corneal regeneration. iScience 2024;27:109641. 10.1016/j.isci.2024.109641<pub-id pub-id-type="pmid">38646166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2024.109641</pub-id><pub-id pub-id-type="pmcid">PMC11031829</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Functional human vascular network generated in photocrosslinkable gelatin methacrylate hydrogels</article-title><source>Adv Funct Mater</source><year>2012</year><volume>22</volume><fpage>2027</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1002/adfm.201101662</pub-id><pub-id pub-id-type="pmid">22907987</pub-id><pub-id pub-id-type="pmcid">PMC3422083</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Chen YC, et al. Functional human vascular network generated in photocrosslinkable gelatin methacrylate hydrogels. Adv Funct Mater. 2012;22:2027&#8211;39.<pub-id pub-id-type="pmid">22907987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.201101662</pub-id><pub-id pub-id-type="pmcid">PMC3422083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayabolen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Native extracellular matrix/fibroin hydrogels for adipose tissue engineering with enhanced vascularization</article-title><source>Biomed Mater</source><year>2017</year><volume>12</volume><fpage>035007</fpage><pub-id pub-id-type="doi">10.1088/1748-605X/aa6a63</pub-id><pub-id pub-id-type="pmid">28361795</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Kayabolen A, et al. Native extracellular matrix/fibroin hydrogels for adipose tissue engineering with enhanced vascularization. Biomed Mater. 2017;12:035007.<pub-id pub-id-type="pmid">28361795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1748-605X/aa6a63</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>K-C</given-names></name><etal/></person-group><article-title>Bioengineering vascularized tissue constructs using an injectable cell-laden enzymatically crosslinked collagen hydrogel derived from dermal extracellular matrix</article-title><source>Acta Biomater</source><year>2015</year><volume>27</volume><fpage>151</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2015.09.002</pub-id><pub-id pub-id-type="pmid">26348142</pub-id><pub-id pub-id-type="pmcid">PMC4624458</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kuo K-C, et al. Bioengineering vascularized tissue constructs using an injectable cell-laden enzymatically crosslinked collagen hydrogel derived from dermal extracellular matrix. Acta Biomater. 2015;27:151&#8211;66.<pub-id pub-id-type="pmid">26348142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2015.09.002</pub-id><pub-id pub-id-type="pmcid">PMC4624458</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>H-Y</given-names></name><etal/></person-group><article-title>The cellular responses of corneal fibroblasts to cyclic stretching loads</article-title><source>Exp Eye Res</source><year>2023</year><volume>237</volume><fpage>109696</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2023.109696</pub-id><pub-id pub-id-type="pmid">37890758</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Tan H-Y, et al. The cellular responses of corneal fibroblasts to cyclic stretching loads. Exp Eye Res. 2023;237:109696.<pub-id pub-id-type="pmid">37890758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2023.109696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavrilova</surname><given-names>N</given-names></name><etal/></person-group><article-title>The effect of biodegradable silk fibroin-based scaffolds containing glial cell line-derived neurotrophic factor (GDNF) on the corneal regeneration process</article-title><source>Int J Biol Macromol</source><year>2021</year><volume>185</volume><fpage>264</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.06.040</pub-id><pub-id pub-id-type="pmid">34119551</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Gavrilova N, et al. The effect of biodegradable silk fibroin-based scaffolds containing glial cell line-derived neurotrophic factor (GDNF) on the corneal regeneration process. Int J Biol Macromol. 2021;185:264&#8211;76.<pub-id pub-id-type="pmid">34119551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2021.06.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samandari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Controlling cellular organization in bioprinting through designed 3D microcompartmentalization</article-title><source>Appl Phys Rev</source><year>2021</year><pub-id pub-id-type="doi">10.1063/5.0040732</pub-id><pub-id pub-id-type="pmid">34084254</pub-id><pub-id pub-id-type="pmcid">PMC8100992</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Samandari M, et al. Controlling cellular organization in bioprinting through designed 3D microcompartmentalization. Appl. Phys. Rev. 2021;8:021404. 10.1063/5.0040732<pub-id pub-id-type="pmid">34084254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1063/5.0040732</pub-id><pub-id pub-id-type="pmcid">PMC8100992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mndlovu</surname><given-names>H</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>du Toit</surname><given-names>LC</given-names></name><name name-style="western"><surname>Choonara</surname><given-names>YE</given-names></name></person-group><article-title>A review of bio material degradation assessment approaches employed in the biomedical field</article-title><source>Npj Mater Degrad</source><year>2024</year><volume>8</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1038/s41529-024-00487-1</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Mndlovu H, Kumar P, du Toit LC, Choonara YE. A review of bio material degradation assessment approaches employed in the biomedical field. Npj Mater Degrad. 2024;8:66.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoseinzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights</article-title><source>Stem Cell Res Ther</source><year>2025</year><volume>16</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s13287-025-04158-z</pub-id><pub-id pub-id-type="pmid">39901306</pub-id><pub-id pub-id-type="pmcid">PMC11792531</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Hoseinzadeh A, et al. Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights. Stem Cell Res Ther. 2025;16:33.<pub-id pub-id-type="pmid">39901306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-025-04158-z</pub-id><pub-id pub-id-type="pmcid">PMC11792531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Idelson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunological properties of human embryonic stem cell-derived retinal pigment epithelial cells</article-title><source>Stem Cell Reports</source><year>2018</year><volume>11</volume><fpage>681</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.07.009</pub-id><pub-id pub-id-type="pmid">30122442</pub-id><pub-id pub-id-type="pmcid">PMC6135721</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Idelson M, et al. Immunological properties of human embryonic stem cell-derived retinal pigment epithelial cells. Stem Cell Reports. 2018;11:681&#8211;95.<pub-id pub-id-type="pmid">30122442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stemcr.2018.07.009</pub-id><pub-id pub-id-type="pmcid">PMC6135721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermankova</surname><given-names>B</given-names></name><etal/></person-group><article-title>The immunomodulatory potential of mesenchymal stem cells in a retinal inflammatory environment</article-title><source>Stem Cell Rev Rep</source><year>2019</year><volume>15</volume><fpage>880</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/s12015-019-09908-0</pub-id><pub-id pub-id-type="pmid">31863334</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hermankova B, et al. The immunomodulatory potential of mesenchymal stem cells in a retinal inflammatory environment. Stem Cell Rev Rep. 2019;15:880&#8211;91.<pub-id pub-id-type="pmid">31863334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12015-019-09908-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>N</given-names></name><name name-style="western"><surname>Brodowski</surname><given-names>L</given-names></name><name name-style="western"><surname>von Kaisenberg</surname><given-names>C</given-names></name><name name-style="western"><surname>Schr&#246;der-Heurich</surname><given-names>B</given-names></name><name name-style="western"><surname>von Versen-H&#246;ynck</surname><given-names>F</given-names></name></person-group><article-title>Cyclosporine A and tacrolimus induce functional impairment and inflammatory reactions in endothelial progenitor cells</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>9696</fpage><pub-id pub-id-type="doi">10.3390/ijms22189696</pub-id><pub-id pub-id-type="pmid">34575860</pub-id><pub-id pub-id-type="pmcid">PMC8472421</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Meyer N, Brodowski L, von Kaisenberg C, Schr&#246;der-Heurich B, von Versen-H&#246;ynck F. Cyclosporine A and tacrolimus induce functional impairment and inflammatory reactions in endothelial progenitor cells. Int J Mol Sci. 2021;22:9696.<pub-id pub-id-type="pmid">34575860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22189696</pub-id><pub-id pub-id-type="pmcid">PMC8472421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X-R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H-C</given-names></name></person-group><article-title>Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study</article-title><source>Eye</source><year>2020</year><volume>34</volume><fpage>1600</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41433-019-0717-3</pub-id><pub-id pub-id-type="pmid">31784702</pub-id><pub-id pub-id-type="pmcid">PMC7608310</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Zhai L-Y, Zhang X-R, Liu H, Ma Y, Xu H-C. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study. Eye. 2020;34:1600&#8211;7.<pub-id pub-id-type="pmid">31784702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41433-019-0717-3</pub-id><pub-id pub-id-type="pmcid">PMC7608310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues-Diez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>27915</fpage><pub-id pub-id-type="doi">10.1038/srep27915</pub-id><pub-id pub-id-type="pmid">27295076</pub-id><pub-id pub-id-type="pmcid">PMC4904742</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Rodrigues-Diez R, et al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep. 2016;6:27915.<pub-id pub-id-type="pmid">27295076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep27915</pub-id><pub-id pub-id-type="pmcid">PMC4904742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddicoat</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>EC</given-names></name></person-group><article-title>Modulation of innate immunity by cyclosporine A</article-title><source>Biochem Pharmacol</source><year>2019</year><volume>163</volume><fpage>472</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2019.03.022</pub-id><pub-id pub-id-type="pmid">30880061</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Liddicoat AM, Lavelle EC. Modulation of innate immunity by cyclosporine A. Biochem Pharmacol. 2019;163:472&#8211;80.<pub-id pub-id-type="pmid">30880061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bcp.2019.03.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacchetta</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00016</pub-id><pub-id pub-id-type="pmid">24550909</pub-id><pub-id pub-id-type="pmcid">PMC3907718</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Bacchetta R, et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. Front Immunol. 2014;5:16.<pub-id pub-id-type="pmid">24550909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00016</pub-id><pub-id pub-id-type="pmcid">PMC3907718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozturk-Oncel</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Impact of poly (dimethylsiloxane) surface modification with conventional and amino acid-conjugated self-assembled monolayers on the differentiation of induced pluripotent stem cells into cardiomyocytes</article-title><source>ACS Biomater Sci Eng</source><year>2021</year><volume>7</volume><fpage>1539</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c01434</pub-id><pub-id pub-id-type="pmid">33724787</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Ozturk-Oncel MO, et al. Impact of poly (dimethylsiloxane) surface modification with conventional and amino acid-conjugated self-assembled monolayers on the differentiation of induced pluripotent stem cells into cardiomyocytes. ACS Biomater Sci Eng. 2021;7:1539&#8211;51.<pub-id pub-id-type="pmid">33724787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsbiomaterials.0c01434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curran</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>JA</given-names></name></person-group><article-title>The guidance of human mesenchymal stem cell differentiation in vitro by controlled modifications to the cell substrate</article-title><source>Biomaterials</source><year>2006</year><volume>27</volume><fpage>4783</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2006.05.001</pub-id><pub-id pub-id-type="pmid">16735063</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Curran JM, Chen R, Hunt JA. The guidance of human mesenchymal stem cell differentiation in vitro by controlled modifications to the cell substrate. Biomaterials. 2006;27:4783&#8211;93.<pub-id pub-id-type="pmid">16735063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2006.05.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pendant small functional groups on poly (&#1013;-caprolactone) substrate modulate adhesion, proliferation and differentiation of human mesenchymal stem cells</article-title><source>Colloids and Surfaces B: Biointerfaces</source><year>2015</year><volume>134</volume><fpage>322</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2015.07.018</pub-id><pub-id pub-id-type="pmid">26209965</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chen M, et al. Pendant small functional groups on poly (&#1013;-caprolactone) substrate modulate adhesion, proliferation and differentiation of human mesenchymal stem cells. Colloids and Surfaces B: Biointerfaces. 2015;134:322&#8211;31.<pub-id pub-id-type="pmid">26209965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.colsurfb.2015.07.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilic Bektas</surname><given-names>C</given-names></name><name name-style="western"><surname>Hasirci</surname><given-names>V</given-names></name></person-group><article-title>Cell loaded gelma: HEMA IPN hydrogels for corneal stroma engineering</article-title><source>J Mater Sci Mater Med</source><year>2020</year><volume>31</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s10856-019-6345-4</pub-id><pub-id pub-id-type="pmid">31811387</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Kilic Bektas C, Hasirci V. Cell loaded gelma: HEMA IPN hydrogels for corneal stroma engineering. J Mater Sci Mater Med. 2020;31:1&#8211;15.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10856-019-6345-4</pub-id><pub-id pub-id-type="pmid">31811387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorkio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Human stem cell based corneal tissue mimicking structures using laser-assisted 3D bioprinting and functional bioinks</article-title><source>Biomaterials</source><year>2018</year><volume>171</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.04.034</pub-id><pub-id pub-id-type="pmid">29684677</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Sorkio A, et al. Human stem cell based corneal tissue mimicking structures using laser-assisted 3D bioprinting and functional bioinks. Biomaterials. 2018;171:57&#8211;71.<pub-id pub-id-type="pmid">29684677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.04.034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Shear-induced alignment of collagen fibrils using 3D cell printing for corneal stroma tissue engineering</article-title><source>Biofabrication</source><year>2019</year><volume>11</volume><fpage>035017</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab1a8b</pub-id><pub-id pub-id-type="pmid">30995622</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Kim H, et al. Shear-induced alignment of collagen fibrils using 3D cell printing for corneal stroma tissue engineering. Biofabrication. 2019;11:035017.<pub-id pub-id-type="pmid">30995622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1758-5090/ab1a8b</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orash</surname><given-names>M</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bioprinted membranes for corneal tissue engineering: a review</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>2797</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14122797</pub-id><pub-id pub-id-type="pmid">36559289</pub-id><pub-id pub-id-type="pmcid">PMC9784133</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Orash M, Salehi A, et al. Bioprinted membranes for corneal tissue engineering: a review. Pharmaceutics. 2022;14:2797.<pub-id pub-id-type="pmid">36559289</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14122797</pub-id><pub-id pub-id-type="pmcid">PMC9784133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Light-activated decellularized extracellular matrix&#8208;based Bioinks for volumetric tissue analogs at the centimeter scale</article-title><source>Adv Funct Mater</source><year>2021</year><volume>31</volume><fpage>2011252</fpage><pub-id pub-id-type="doi">10.1002/adfm.202011252</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Kim H, et al. Light-activated decellularized extracellular matrix&#8208;based Bioinks for volumetric tissue analogs at the centimeter scale. Adv Funct Mater. 2021;31:2011252.</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comtois-Bona</surname><given-names>ME</given-names></name><etal/></person-group><article-title>3D-Printed Low&#8208;Cost artificial corneal perfusion chamber for investigating corneal physiology and diseases in different animal species</article-title><source>Adv Eng Mater</source><year>2023</year><volume>25</volume><fpage>2300695</fpage><pub-id pub-id-type="doi">10.1002/adem.202300695</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Comtois-Bona ME, et al. 3D-Printed Low&#8208;Cost artificial corneal perfusion chamber for investigating corneal physiology and diseases in different animal species. Adv Eng Mater. 2023;25:2300695.</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Bioprinting three-dimensional cell-laden tissue constructs with controllable degradation</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>24474</fpage><pub-id pub-id-type="doi">10.1038/srep24474</pub-id><pub-id pub-id-type="pmid">27091175</pub-id><pub-id pub-id-type="pmcid">PMC4835808</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Wu Z, et al. Bioprinting three-dimensional cell-laden tissue constructs with controllable degradation. Sci Rep. 2016;6:24474.<pub-id pub-id-type="pmid">27091175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep24474</pub-id><pub-id pub-id-type="pmcid">PMC4835808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aramant</surname><given-names>RB</given-names></name><name name-style="western"><surname>Seiler</surname><given-names>MJ</given-names></name></person-group><article-title>Progress in retinal sheet transplantation</article-title><source>Prog Retin Eye Res</source><year>2004</year><volume>23</volume><fpage>475</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2004.05.003</pub-id><pub-id pub-id-type="pmid">15302347</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Aramant RB, Seiler MJ. Progress in retinal sheet transplantation. Prog Retin Eye Res. 2004;23:475&#8211;94.<pub-id pub-id-type="pmid">15302347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preteyeres.2004.05.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S</given-names></name></person-group><article-title>Transplantation of photoreceptors to light-damaged retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>1989</year><volume>30</volume><fpage>1684</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">2527211</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Silverman M, Hughes S. Transplantation of photoreceptors to light-damaged retina. Invest Ophthalmol Vis Sci. 1989;30:1684&#8211;90.<pub-id pub-id-type="pmid">2527211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Alonso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Current insights into 3D bioprinting: an advanced approach for eye tissue regeneration</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>308</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13030308</pub-id><pub-id pub-id-type="pmid">33653003</pub-id><pub-id pub-id-type="pmcid">PMC7996883</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Ruiz-Alonso S, et al. Current insights into 3D bioprinting: an advanced approach for eye tissue regeneration. Pharmaceutics. 2021;13:308.<pub-id pub-id-type="pmid">33653003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13030308</pub-id><pub-id pub-id-type="pmcid">PMC7996883</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>EHY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>3D bioprinting for next-generation personalized medicine</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>6357</fpage><pub-id pub-id-type="doi">10.3390/ijms24076357</pub-id><pub-id pub-id-type="pmid">37047328</pub-id><pub-id pub-id-type="pmcid">PMC10094501</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Lam EHY, Yu F, Zhu S, Wang Z. 3D bioprinting for next-generation personalized medicine. Int J Mol Sci. 2023;24:6357.<pub-id pub-id-type="pmid">37047328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24076357</pub-id><pub-id pub-id-type="pmcid">PMC10094501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masaeli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tissue engineering of retina through high resolution 3-dimensional inkjet bioprinting</article-title><source>Biofabrication</source><year>2020</year><volume>12</volume><fpage>025006</fpage><pub-id pub-id-type="doi">10.1088/1758-5090/ab4a20</pub-id><pub-id pub-id-type="pmid">31578006</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Masaeli E, et al. Tissue engineering of retina through high resolution 3-dimensional inkjet bioprinting. Biofabrication. 2020;12:025006.<pub-id pub-id-type="pmid">31578006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1088/1758-5090/ab4a20</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>A bioprinted bruch&#8217;s membrane for modeling smoke-induced retinal pigment epithelium degeneration via hybrid membrane printing technology</article-title><source>Adv Healthc Mater</source><year>2022</year><volume>11</volume><fpage>2200728</fpage><pub-id pub-id-type="doi">10.1002/adhm.202200728</pub-id><pub-id pub-id-type="pmid">35841587</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Kim J, et al. A bioprinted bruch&#8217;s membrane for modeling smoke-induced retinal pigment epithelium degeneration via hybrid membrane printing technology. Adv Healthc Mater. 2022;11:2200728.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202200728</pub-id><pub-id pub-id-type="pmid">35841587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Maturation and protection effect of retinal tissue-derived bioink for 3D cell printing technology</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>934</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13070934</pub-id><pub-id pub-id-type="pmid">34201702</pub-id><pub-id pub-id-type="pmcid">PMC8309106</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Kim J, et al. Maturation and protection effect of retinal tissue-derived bioink for 3D cell printing technology. Pharmaceutics. 2021;13:934.<pub-id pub-id-type="pmid">34201702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13070934</pub-id><pub-id pub-id-type="pmcid">PMC8309106</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Bioprinted 3D outer retina barrier uncovers RPE-dependent choroidal phenotype in advanced macular degeneration</article-title><source>Nat Methods</source><year>2023</year><volume>20</volume><fpage>149</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/s41592-022-01701-1</pub-id><pub-id pub-id-type="pmid">36550275</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Song MJ, et al. Bioprinted 3D outer retina barrier uncovers RPE-dependent choroidal phenotype in advanced macular degeneration. Nat Methods. 2023;20:149&#8211;61.<pub-id pub-id-type="pmid">36550275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-022-01701-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>TS</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>WS</given-names></name><name name-style="western"><surname>Chang</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Koh</surname><given-names>KS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J-W</given-names></name></person-group><article-title>Customized orbital wall reconstruction using three-dimensionally printed rapid prototype model in patients with orbital wall fracture</article-title><source>J Craniofac Surg</source><year>2016</year><volume>27</volume><fpage>2020</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/SCS.0000000000003195</pub-id><pub-id pub-id-type="pmid">28005746</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Oh TS, Jeong WS, Chang TJ, Koh KS, Choi J-W. Customized orbital wall reconstruction using three-dimensionally printed rapid prototype model in patients with orbital wall fracture. J Craniofac Surg. 2016;27:2020&#8211;4.<pub-id pub-id-type="pmid">28005746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SCS.0000000000003195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debellemani&#232;re</surname><given-names>G</given-names></name><name name-style="western"><surname>Flores</surname><given-names>M</given-names></name><name name-style="western"><surname>Montard</surname><given-names>M</given-names></name><name name-style="western"><surname>Delbosc</surname><given-names>B</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>M</given-names></name></person-group><article-title>Three-dimensional printing of optical lenses and ophthalmic surgery: challenges and perspectives</article-title><source>J Refract Surg</source><year>2016</year><volume>32</volume><fpage>201</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3928/1081597X-20160121-05</pub-id><pub-id pub-id-type="pmid">27027628</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Debellemani&#232;re G, Flores M, Montard M, Delbosc B, Saleh M. Three-dimensional printing of optical lenses and ophthalmic surgery: challenges and perspectives. J Refract Surg. 2016;32:201&#8211;4.<pub-id pub-id-type="pmid">27027628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3928/1081597X-20160121-05</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><etal/></person-group><article-title>A micro-contoured contact lens for delivering 3D-printed ABCB5-positive stem cells for corneal regeneration</article-title><source>Investig Ophthalmol Vis Sci</source><year>2022</year><volume>63</volume><fpage>3628</fpage><lpage>A0193</lpage></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Lee C, et al. A micro-contoured contact lens for delivering 3D-printed ABCB5-positive stem cells for corneal regeneration. Investig Ophthalmol Vis Sci. 2022;63:3628&#8211;A0193.</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>3D printed punctal plugs for controlled ocular drug delivery</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>1421</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13091421</pub-id><pub-id pub-id-type="pmid">34575497</pub-id><pub-id pub-id-type="pmcid">PMC8464872</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Xu X, et al. 3D printed punctal plugs for controlled ocular drug delivery. Pharmaceutics. 2021;13:1421.<pub-id pub-id-type="pmid">34575497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13091421</pub-id><pub-id pub-id-type="pmcid">PMC8464872</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>TM</given-names></name></person-group><article-title>Semipermeable microcapsules</article-title><source>Science</source><year>1964</year><volume>146</volume><fpage>524</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.146.3643.524</pub-id><pub-id pub-id-type="pmid">14190240</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Chang TM. Semipermeable microcapsules. Science. 1964;146:524&#8211;5.<pub-id pub-id-type="pmid">14190240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.146.3643.524</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soon-Shiong</surname><given-names>P</given-names></name><etal/></person-group><article-title>Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>950</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)90067-1</pub-id><pub-id pub-id-type="pmid">7909011</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Soon-Shiong P, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994;343:950&#8211;1.<pub-id pub-id-type="pmid">7909011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(94)90067-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emerich</surname><given-names>DF</given-names></name><name name-style="western"><surname>Orive</surname><given-names>G</given-names></name><name name-style="western"><surname>Thanos</surname><given-names>C</given-names></name><name name-style="western"><surname>Tornoe</surname><given-names>J</given-names></name><name name-style="western"><surname>Wahlberg</surname><given-names>L</given-names></name></person-group><article-title>U. Encapsulated cell therapy for neurodegenerative diseases: from promise to product</article-title><source>Adv Drug Deliv Rev</source><year>2014</year><volume>67</volume><fpage>131</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2013.07.008</pub-id><pub-id pub-id-type="pmid">23880505</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Emerich DF, Orive G, Thanos C, Tornoe J, Wahlberg L. U. Encapsulated cell therapy for neurodegenerative diseases: from promise to product. Adv Drug Deliv Rev. 2014;67:131&#8211;41.<pub-id pub-id-type="pmid">23880505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2013.07.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauper</surname><given-names>K</given-names></name><etal/></person-group><article-title>Continuous intraocular drug delivery lasting over a decade: ciliary neurotrophic factor (CNTF) secreted from neurotech&#8217;s NT-501 implanted in subjects with retinal degenerative disorders</article-title><source>Investig Ophthalmol Vis Sci</source><year>2023</year><volume>64</volume><fpage>3680</fpage><lpage>3680</lpage></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Kauper K, et al. Continuous intraocular drug delivery lasting over a decade: ciliary neurotrophic factor (CNTF) secreted from neurotech&#8217;s NT-501 implanted in subjects with retinal degenerative disorders. Investig Ophthalmol Vis Sci. 2023;64:3680&#8211;3680.</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loewenstein</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interim results of a dose escalation study of NT-503 encapsulated cell therapy for the treatment of choroidal neovascularization in AMD</article-title><source>Investig Ophthalmol Vis Sci</source><year>2015</year><volume>56</volume><fpage>2277</fpage><lpage>2277</lpage></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Loewenstein A, et al. Interim results of a dose escalation study of NT-503 encapsulated cell therapy for the treatment of choroidal neovascularization in AMD. Investig Ophthalmol Vis Sci. 2015;56:2277&#8211;2277.</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bush</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>2420</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1167/iovs.03-1342</pub-id><pub-id pub-id-type="pmid">15223826</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Bush RA, et al. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci. 2004;45:2420&#8211;30.<pub-id pub-id-type="pmid">15223826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.03-1342</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauper</surname><given-names>K</given-names></name><etal/></person-group><article-title>Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><fpage>7484</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9970</pub-id><pub-id pub-id-type="pmid">23049090</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Kauper K, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53:7484&#8211;91.<pub-id pub-id-type="pmid">23049090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.12-9970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>6241</fpage><lpage>6245</lpage><pub-id pub-id-type="doi">10.1073/pnas.1018987108</pub-id><pub-id pub-id-type="pmid">21444807</pub-id><pub-id pub-id-type="pmcid">PMC3076847</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Zhang K, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:6241&#8211;5.<pub-id pub-id-type="pmid">21444807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1018987108</pub-id><pub-id pub-id-type="pmcid">PMC3076847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birch</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa</article-title><source>Am J Ophthalmol</source><year>2013</year><volume>156</volume><fpage>283</fpage><lpage>292.e281</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2013.03.021</pub-id><pub-id pub-id-type="pmid">23668681</pub-id><pub-id pub-id-type="pmcid">PMC4111936</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Birch DG, et al. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013;156:283-292.e281.<pub-id pub-id-type="pmid">23668681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajo.2013.03.021</pub-id><pub-id pub-id-type="pmcid">PMC4111936</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chew</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2</article-title><source>NEJM Evid</source><year>2025</year><volume>4</volume><fpage>EVIDoa2400481</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2400481</pub-id><pub-id pub-id-type="pmid">40693847</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Chew EY, et al. Cell-based ciliary neurotrophic factor therapy for macular telangiectasia type 2. NEJM Evid. 2025;4:EVIDoa2400481.<pub-id pub-id-type="pmid">40693847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/EVIDoa2400481</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>H</given-names></name><etal/></person-group><article-title>A 3D printed self-sustainable cell-encapsulation drug delivery device for periocular transplant-based treatment of retinal degenerative diseases</article-title><source>Micromachines</source><year>2020</year><volume>11</volume><fpage>436</fpage><pub-id pub-id-type="doi">10.3390/mi11040436</pub-id><pub-id pub-id-type="pmid">32326233</pub-id><pub-id pub-id-type="pmcid">PMC7231335</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Kojima H, et al. A 3D printed self-sustainable cell-encapsulation drug delivery device for periocular transplant-based treatment of retinal degenerative diseases. Micromachines. 2020;11:436.<pub-id pub-id-type="pmid">32326233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/mi11040436</pub-id><pub-id pub-id-type="pmcid">PMC7231335</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annamalai</surname><given-names>B</given-names></name><etal/></person-group><article-title>Encapsulated cell technology-based delivery of a complement inhibitor reduces choroidal neovascularization in a mouse model</article-title><source>Transl Vis Sci Technol</source><year>2018</year><volume>7</volume><fpage>3</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1167/tvst.7.2.3</pub-id><pub-id pub-id-type="pmid">29576927</pub-id><pub-id pub-id-type="pmcid">PMC5846441</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Annamalai B, et al. Encapsulated cell technology-based delivery of a complement inhibitor reduces choroidal neovascularization in a mouse model. Transl Vis Sci Technol. 2018;7:3&#8211;3.<pub-id pub-id-type="pmid">29576927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/tvst.7.2.3</pub-id><pub-id pub-id-type="pmcid">PMC5846441</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>E</given-names></name><etal/></person-group><article-title>Optimization of 100 &#181;m alginate-poly-l-lysine-alginate capsules for intravitreous administration</article-title><source>J Controlled Release</source><year>2012</year><volume>158</volume><fpage>443</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.09.079</pub-id><pub-id pub-id-type="pmid">21971294</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Santos E, et al. Optimization of 100 &#181;m alginate-poly-l-lysine-alginate capsules for intravitreous administration. J Controlled Release. 2012;158:443&#8211;50.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2011.09.079</pub-id><pub-id pub-id-type="pmid">21971294</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>FS</given-names></name><name name-style="western"><surname>Wong</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>BP</given-names></name><name name-style="western"><surname>Lo</surname><given-names>AC</given-names></name></person-group><article-title>Sustained delivery of bioactive GDNF from collagen and alginate-based cell-encapsulating gel promoted photoreceptor survival in an inherited retinal degeneration model</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><fpage>e0159342</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0159342</pub-id><pub-id pub-id-type="pmid">27441692</pub-id><pub-id pub-id-type="pmcid">PMC4956057</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Wong FS, Wong CC, Chan BP, Lo AC. Sustained delivery of bioactive GDNF from collagen and alginate-based cell-encapsulating gel promoted photoreceptor survival in an inherited retinal degeneration model. PLoS ONE. 2016;11:e0159342.<pub-id pub-id-type="pmid">27441692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0159342</pub-id><pub-id pub-id-type="pmcid">PMC4956057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kontturi</surname><given-names>L-S</given-names></name><etal/></person-group><article-title>Encapsulated cells for long-term secretion of soluble VEGF receptor 1: material optimization and simulation of ocular drug response</article-title><source>Eur J Pharm Biopharm</source><year>2015</year><volume>95</volume><fpage>387</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.10.005</pub-id><pub-id pub-id-type="pmid">25460143</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Kontturi L-S, et al. Encapsulated cells for long-term secretion of soluble VEGF receptor 1: material optimization and simulation of ocular drug response. Eur J Pharm Biopharm. 2015;95:387&#8211;97.<pub-id pub-id-type="pmid">25460143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2014.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banou</surname><given-names>L</given-names></name><name name-style="western"><surname>Sarrafpour</surname><given-names>S</given-names></name><name name-style="western"><surname>Teng</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Ocular gene therapy: an overview of viral vectors, immune responses, and future directions</article-title><source>Yale J Biol Med</source><year>2024</year><volume>97</volume><fpage>491</fpage><pub-id pub-id-type="doi">10.59249/HWID7537</pub-id><pub-id pub-id-type="pmid">39703610</pub-id><pub-id pub-id-type="pmcid">PMC11650918</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Banou L, Sarrafpour S, Teng CC, Liu J. Ocular gene therapy: an overview of viral vectors, immune responses, and future directions. Yale J Biol Med. 2024;97:491.<pub-id pub-id-type="pmid">39703610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.59249/HWID7537</pub-id><pub-id pub-id-type="pmcid">PMC11650918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrero-Naranjo</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration</article-title><source>Investig Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><fpage>3298</fpage><lpage>3298</lpage></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Guerrero-Naranjo JL, et al. Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration. Investig Ophthalmol Vis Sci. 2013;54:3298&#8211;3298.</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Encapsulated cell technology: delivering cytokines to treat posterior ocular diseases</article-title><source>Pharmacol Res</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.phrs.2024.107159</pub-id><pub-id pub-id-type="pmid">38554790</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Wang J, et al. Encapsulated cell technology: Delivering cytokines to treat posterior ocular diseases. Pharmacol Res. 2024;203:107159. 10.1016/j.phrs.2024.107159<pub-id pub-id-type="pmid">38554790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2024.107159</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhise</surname><given-names>MG</given-names></name><name name-style="western"><surname>Patel</surname><given-names>L</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name></person-group><article-title>3D printed medical devices: regulatory standards and technological advancements in the USA, Canada and Singapore-a cross-national study</article-title><source>Int J Pharm Investig</source><year>2024</year><pub-id pub-id-type="doi">10.5530/ijpi.14.3.99</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Bhise MG, Patel L, Patel K. 3D printed medical devices: regulatory standards and technological advancements in the USA, Canada and Singapore-a cross-national study. Int J Pharm Investig. 2024;888&#8211;902. 10.5530/ijpi.14.3.99</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>